PO.PS01.07 · 人群科学
套细胞淋巴瘤全基因组关联研究发现新的易感位点,提示B细胞染色质阅读器与DNA修复机制发挥关键作用
Genome-wide association study of mantle cell lymphoma identifies novel loci suggesting a critical role for B-cell chromatin readers and DNA repair mechanisms
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:套细胞淋巴瘤(MCL)是一种侵袭性、罕见的B细胞非霍奇金淋巴瘤,即使接受治疗预后仍差。尽管其临床意义重大,MCL的病因在很大程度上仍不明确。一些研究报告其与家族史存在正相关,提示遗传因素可能参与风险形成。方法:为鉴定与风险相关的种系遗传变异,我们开展了首个MCL全基因组关联研究(GWAS)及GWAS荟萃分析,纳入1,163例病例和61,271例对照。最显著的位点进入三项独立研究进行验证,包括576例病例和771,773例对照。为鉴定所发现位点的潜在靶基因和通路,我们进行了F-MAGMA、共定位以及全转录组关联研究(TWAS)分析。为深入了解潜在的调控机制,我们采用FORGE2框架,利用多种细胞类型的DNase I高敏位点和组蛋白标记ChIP-seq数据进行了整合表观基因组分析。结果:在联合分析中,我们鉴定出8个与MCL风险相关的全基因组显著位点(P<5x10^-8),其中若干位点位于具有已知DNA修复(ATM)、端粒(TERT)或RNA结合功能(RBM20)的基因附近。进一步使用F-MAGMA分析(该方法利用DNase-seq数据从GWAS中优先筛选基因)鉴定出与风险显著相关的基因,包括SP140——一种染色质阅读器和病原体应答的免疫调节因子。该基因在全血中与我们的主导变异也表现出强共定位(COLOC后验概率PP4=0.97)。TWAS显示与SP140以及与细胞增殖相关的ACTA2存在显著关联(P<3x10^-6)。在B淋巴细胞和T淋巴细胞中观察到DNase I高敏位点的富集(q值<0.05),为其在免疫细胞特异性调控区域中的作用提供了证据。在B细胞中观察到增强子相关组蛋白标记H3K4me1的富集(q值<0.01),凸显了免疫细胞特异性增强子的作用。转录因子(TF)基序富集分析指向对B细胞发育和分化至关重要的转录因子,尤其是TCF3和EP300(二者q<0.01),提示B细胞谱系调控与MCL风险之间存在关联。最后,基于全基因组SNP的遗传率估计为17%,凸显了常见变异在MCL风险中的重要性。结论:本研究通过鉴定8个显著位点并估计出可观的常见变异遗传率,为MCL的遗传易感性提供了新的见解。这些发现凸显了若干不同生物学通路——特别是DNA修复、端粒酶功能和B细胞分化——在MCL病因中的作用,为机制研究提供了新的靶点。
查看英文原文 English abstract
Background: Mantle cell lymphoma (MCL) is an aggressive and rare B-cell non-Hodgkin lymphoma with poor prognosis, even with treatment. Despite its clinical importance, the etiology of MCL remains largely unknown. Some studies have reported a positive association with family history, suggesting that genetic factors could contribute to risk. Methods: To identify germline genetic variants associated with risk, we conducted the first genome-wide association studies (GWAS) and GWAS meta-analysis for MCL, comprising 1,163 cases and 61,271 controls. The most significant loci were taken forward for replication in three independent studies, including 576 cases and 771,773 controls. To identify potential target genes and pathways of discovered loci, we conducted F-MAGMA, colocalization, and transcriptome-wide association study (TWAS) analyses. To gain insight into underlying regulatory mechanisms, we performed integrative epigenomic analyses using DNase I hotspots and histone mark ChIP-seq data across diverse cell types applying the FORGE2 framework. Results: In the joint analyses, we identified eight genome-wide significant loci (P<5x10 -8 ) associated with MCL risk, several of which were located near genes with known DNA repair (ATM), telomere (TERT), or RNA-binding functions (RBM20). Further analyses using F-MAGMA, which uses DNase-seq data to prioritize genes from GWAS, identified genes that were significantly associated with risk, including SP140, a chromatin reader and immune regulator of pathogen response. This gene also displayed strong colocalization with our lead variant in whole blood (COLOC posterior probability PP4=0.97). TWAS demonstrated significant associations with SP140 and ACTA2, which has been linked to cell proliferation (P<3x10 -6 ). Enrichment for DNase I hotspots was observed in B and T lymphocytes (q-value<0.05), providing evidence for a role in immune cell-specific regulatory regions. Enrichment for enhancer-associated histone mark H3K4me1 was observed in B cells (q-value<0.01), highlighting a role for immune cell-specific enhancers. Transcription factor (TF) motif enrichment analysis pointed to TFs critical for B-cell development and differentiation, notably TCF3 and EP300 (q<0.01 for both), suggesting an association between B-cell lineage regulation and MCL risk. Finally, genome-wide SNP-based heritability was estimated to be 17%, underscoring the importance of common variants in MCL risk. Conclusion: Our study provides novel insight into the inherited susceptibility of MCL by identifying eight significant loci and estimating substantial common variant heritability. These findings highlight a role for several distinct biological pathways -specifically DNA repair, telomerase function, and B-cell differentiation- in the etiology of MCL, offering new targets for mechanistic investigation.
利益披露 Disclosure
C. E. Breeze, None..
A. Clay-Gilmour, None..
H. A. Park, None..
Ó. B. Davíðsson, None..
A. Macauda, None..
B. M. Birmann, None..
E. E. Brown, None..
M. Güler, None..
M. A. Hildebrandt, None..
A. Nieters, None..
K. Ong, None..
J. Biel-Nielsen Dietz, None..
K. E. Smedby, None..
K. Smith-Byrne, None..
R. Griffin, None..
S. S. Wang, None..
S. Slager, None..
J. R. Cerhan, None..
J. N. Hofmann, None..
Q. Lan, None..
N. Rothman, None..
I. Glimelius, None..
H. Hjalgrim, None..
J. Mckay, None..
S. I. Berndt, None.